BioWorld

Feb. 21, 2007

Shire Buying Vyvanse Partner New River For $64 Per Share

Shire plc, which partnered with New River Pharmaceuticals Inc. two years on a drug for attention deficit hyperactivity disorder, agreed to acquire the smaller firm for $2.6 billion in cash. (BioWorld Today) Read More

Lux Starts Phase III Studies; Isotechnika Raises $34.5M

New Autism Clues As Prevalence Estimates Increase Once Again

Caprion, Ecopia Merger Gets $45M Pledge From Investors

Theratechnologies Bringing In C$52.5M To Fund Phase III Trial

BioMarin Pharma Misses With Phase IIa Hypertension Trial

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...